NO20030588L - Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander - Google Patents

Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander

Info

Publication number
NO20030588L
NO20030588L NO20030588A NO20030588A NO20030588L NO 20030588 L NO20030588 L NO 20030588L NO 20030588 A NO20030588 A NO 20030588A NO 20030588 A NO20030588 A NO 20030588A NO 20030588 L NO20030588 L NO 20030588L
Authority
NO
Norway
Prior art keywords
prophylaxis
rejection
treatment
receptor antagonists
cardiovascular conditions
Prior art date
Application number
NO20030588A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030588D0 (no
Inventor
Mireille Marguerite J Bonhomme
Antoine Michel Alain Bril
Bernard Emile Joseph Gout
Bela Rajiv Patel
Gillian Louise Shepherd
Neeta Balkrishan Amin
Bernard Enno Ilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20030588D0 publication Critical patent/NO20030588D0/no
Publication of NO20030588L publication Critical patent/NO20030588L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20030588A 2000-08-07 2003-02-06 Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander NO20030588L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Publications (2)

Publication Number Publication Date
NO20030588D0 NO20030588D0 (no) 2003-02-06
NO20030588L true NO20030588L (no) 2003-04-03

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030588A NO20030588L (no) 2000-08-07 2003-02-06 Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander

Country Status (16)

Country Link
US (3) US20050032866A1 (enExample)
EP (1) EP1311295A2 (enExample)
JP (2) JP2004505930A (enExample)
KR (1) KR20030027010A (enExample)
CN (1) CN100413539C (enExample)
AU (1) AU781276B2 (enExample)
BR (1) BR0113073A (enExample)
CA (1) CA2418904A1 (enExample)
CZ (1) CZ2003366A3 (enExample)
HU (1) HUP0303075A3 (enExample)
IL (1) IL154279A0 (enExample)
MX (1) MXPA03001210A (enExample)
NO (1) NO20030588L (enExample)
NZ (1) NZ524108A (enExample)
PL (1) PL365048A1 (enExample)
WO (1) WO2002011766A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007857A (es) * 2002-02-14 2004-10-15 Glaxo Group Ltd Composicion farmaceutica que comprende n-((1-butil -4-piperidinil) metil)-3, 4-dihidro-2h -(1, 3)oxazino (3, 2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco.
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
EP3176164B1 (en) 2014-07-30 2019-08-21 Aetas Pharma Co. Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
CA2118812C (en) * 1991-09-12 2006-01-17 Francis David King 5-ht4 receptor antagonists
MA22647A1 (fr) * 1991-09-14 1993-04-01 Smithkline Beecham Plc Procede de preparation d'un ester ou d'un amide d'un nouveau produit .
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
DE69325167T2 (de) * 1992-03-12 2000-01-20 Smithkline Beecham P.L.C., Brentford Kondensierte indol-derivate als 5-ht4-rezeptor-antagonisten
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
MX9301837A (es) * 1992-03-31 1994-02-28 Glaxo Group Ltd Ureas y fenilcarbamatos substituidos, proceso para su preparacion y composicion farmaceutica que los comprende.
SK116394A3 (en) * 1992-03-31 1995-04-12 Glaxo Group Ltd Substituted phenylcarbamates and ureas
ATE171446T1 (de) * 1993-05-26 1998-10-15 Syntex Inc 1-phenylalkanone als 5-ht4 rezeptor ligande
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
ES2151743T3 (es) * 1996-08-16 2001-01-01 Smithkline Beecham Plc Procedimiento para la preparacion de n-((1-n-butil-4-piperidinil)metil)-3,4-dihidro-2h-(1,3)-oxazino(3,2-a)indol-10-carboxamida y las sales y productos intermedios en el procedimiento.
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Also Published As

Publication number Publication date
CN100413539C (zh) 2008-08-27
BR0113073A (pt) 2004-06-22
HUP0303075A3 (en) 2007-03-28
JP2004505930A (ja) 2004-02-26
EP1311295A2 (en) 2003-05-21
MXPA03001210A (es) 2004-08-12
PL365048A1 (en) 2004-12-27
US20050032866A1 (en) 2005-02-10
WO2002011766A2 (en) 2002-02-14
WO2002011766A3 (en) 2002-08-01
IL154279A0 (en) 2003-09-17
NO20030588D0 (no) 2003-02-06
US20070015769A1 (en) 2007-01-18
CZ2003366A3 (en) 2004-04-14
US20080125422A1 (en) 2008-05-29
CN1468112A (zh) 2004-01-14
AU781276B2 (en) 2005-05-12
AU7652901A (en) 2002-02-18
HUP0303075A2 (hu) 2003-12-29
NZ524108A (en) 2004-11-26
CA2418904A1 (en) 2002-02-14
KR20030027010A (ko) 2003-04-03
JP2007145869A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
NO20034169L (no) MCH-antagonister og deres anvendelse ved behandling av fedme
NO20013340D0 (no) Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser
DE60003148D1 (de) Bestimmung der Cachezeit
DE60112791D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
NO20024682D0 (no) Kombinert anvendelse av anti-cytokin-antistoff eller antagonister og anti-CD20 ved behandling av B-celle-lymfom
DE60037322D1 (de) Verwendung des Organopolysiloxans M3T in kosmetischen Zusammensetzungen
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
DE60037213D1 (de) Verwendung von Reinigungsgas
DK1231920T3 (da) Anvendelse af epinastin til behandling af allergisk rhinitis/conjunctivitis
ITMI20011351A0 (it) Gruppo di svuotamento per il recupero del residuo di fondo particolarmente in filtei essicatori essicatori e simili
DK1530466T3 (da) Anvendelse af nintedanib til behandling af lungefibrose
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
NO20033443L (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
NO20030588L (no) Anvendelse av 5HT4-reseptorantagonister ved profylakse eller behandling avvisse kardiovaskul¶re tilstander
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE60009587D1 (de) Bestimmung des Papierstandes
NO20014130D0 (no) Epitoper eller mimotoper avledet fra C-<epsilon>2-domenet hos IgE, antagonister derav og deres terapeutiske anvendelser
NO20033388D0 (no) Anvendelse av GAL3-reseptorantagonister ved behandling av depresjon og/eller angst samt forbindelser som er anvendelige ved slik behandling
NO20005386L (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
EP1278216A4 (en) ELECTROLYTIC SOLUTION FOR ELECTROLYTE CONDENSER AND THEREOF USING ELECTROLYTE CONDENSER
NO20020008D0 (no) Anvendelse av cortisol antagonister i behandling av hjertesvikt
DE60016769D1 (de) Antagonisten des vitronectin-receptors
NO20004142L (no) Ftalimidoarylpiperaziner som <alfa> 1A reseptorantagonister anvendelige ved behandling av benign prostatahyperplasi
HUP0300754A3 (en) Use of il-8 receptor antagonists in the treatment of virus infections
AU782870C (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application